A Multi-Centre, Open label, Randomized (1:1), Parallel, Phase II Study to evaluate the Safety, Tolerability and Immunogenicity of a 15-Valent Pneumococcal Conjugate Vaccine (PCV15) in healthy subjects between 2-5 years of age (Group I: 15-Valent Pneumococcal Conjugate Vaccine, Group II: Prevnar 13)
Latest Information Update: 21 Jan 2020
At a glance
- Drugs PCV 15 Tergene Biotech (Primary)
- Indications Pneumonia
- Focus Adverse reactions
- Sponsors Tergene Biotech
Most Recent Events
- 10 Jan 2020 Status changed from recruiting to completed.
- 25 Sep 2019 New trial record